Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lirilumab

- PMLiVE

BMS launches hepatitis C pill Daklinza in the UK

Will be offered as a combination treatment with Gilead's Solvadi

Elliott Levy joins Amgen from BMS

He is appointed senior VP, global development

Bristol-Myers Squibb (BMS) building

BMS creates US academic tie-up to foster biopharma research

Partnership with investment firm could also boost its pipeline

Bristol-Myers Squibb (BMS) building

BMS files fixed-dose HIV combination in US

Combines Reyataz with Gilead Sciences' cobicistat

Bristol-Myers Squibb (BMS) building

BMS strikes $350m deal to boost its immuno-oncology pipeline

Will collaborate with US biotech Five Prime Therapeutics

Bristol-Myers Squibb (BMS) building

BMS’ novel HIV drug clears phase II trial

Entry inhibitor BMS-660368 moves closer to first-in-class approval

Bristol-Myers Squibb (BMS) building

BMS’ oral hepatitis C regimen gets breakthrough status

Combines daclatasvir and asunepravir

Bristol-Myers Squibb (BMS) building

BMS exits hep C, diabetes and neuroscience drug discovery

Will discontinue 'broad-based discovery work' in the therapy areas

- PMLiVE

Novo’s Wagtmann joins Innate as chief scientific officer

He was previously head of inflammation biology at Danish pharma company

Bristol-Myers Squibb (BMS) building

BMS signs 10-year biologic manufacturing deal with Samsung

Agreement covers one of the pharma company's antibody cancer drugs

- PMLiVE

BMS’ Orencia matches Humira in arthritis study

Data should help drug establish itself against AbbVie's market-leading RA medicine

- PMLiVE

BMS wins wider NICE Orencia arthritis approval

But only after cutting the drug's price

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links